Mirum Pharmaceuticals Inc
$ 94.11
-11.04%
06 Aug - close price
- Market Cap 6,451,204,000 USD
- Current Price $ 94.11
- High / Low $ 97.00 / 88.88
- Stock P/E N/A
- Book Value 3.98
- EPS -13.79
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.06 %
- ROE -3.36 %
- 52 Week High 130.00
- 52 Week Low 58.48
About
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of an advanced line of novel therapies for debilitating liver diseases. The company is headquartered in Foster City, California.
Analyst Target Price
$146.50
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-30 | 2026-05-06 | 2026-02-25 | 2025-11-04 | 2025-08-06 | 2025-05-07 | 2025-02-26 | 2024-11-12 | 2024-08-07 | 2024-05-08 | 2024-02-28 | 2023-11-02 |
| Reported EPS | -0.8 | -1.08 | -0.12 | 0.05 | -0.12 | -0.3 | -0.49 | -0.3 | -0.52 | -0.54 | -0.66 | -0.57 |
| Estimated EPS | -0.77 | -0.35 | -0.0486 | -0.16 | -0.33 | -0.27 | -0.2466 | -0.45 | -0.46 | -0.3 | -0.24 | -0.81 |
| Surprise | -0.03 | -0.73 | -0.0714 | 0.21 | 0.21 | -0.03 | -0.2434 | 0.15 | -0.06 | -0.24 | -0.42 | 0.24 |
| Surprise Percentage | -3.8961% | -208.5714% | -146.9136% | 131.25% | 63.6364% | -11.1111% | -98.7024% | 33.3333% | -13.0435% | -80% | -175% | 29.6296% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MIRM
2026-08-06 18:40:27
H.C. Wainwright has reduced its target price for Mirum Pharmaceuticals Inc. (MIRM.O) from $185 to $140. This announcement was made on August 6, 2026, according to a Reuters report published on Bitget News. The article explicitly states that its content reflects the author's opinion and should not be used for investment decisions.
2026-08-06 17:12:48
Mirum Pharmaceuticals, Inc.'s average 12-month price target has been lowered to $138.21 from $145.29, according to 14 analysts. Despite the cut, the new target still suggests a 31% potential upside from the Aug. 5 closing price. The consensus rating remains a "Buy" across all covering analysts.
2026-08-06 16:13:07
Mirum Pharmaceuticals (MIRM) stock dropped 10.4% after the FDA recommended a Phase 3 study for its drug volixibat, delaying its potential NDA submission despite strong second-quarter sales and raised full-year guidance. The regulatory setback for volixibat, intended for cholestatic pruritus due to PSC, has raised investor concerns about the timeline and execution risk for this key pipeline program. Insiders have sold off shares, while institutional investors show mixed activity, with some significantly adding to their holdings.
2026-08-06 14:13:07
RBC Capital has lowered its price target for Mirum Pharmaceuticals (MIRM) from $148 to $135, while still maintaining an Outperform rating on the stock. This adjustment comes after the company recently reported its Q2 2026 earnings, which showed a wider loss despite increased revenue. Mirum Pharmaceuticals is a biopharmaceutical company focused on rare diseases, with key products like LIVMARLI and Cholbam.
2026-08-06 14:12:48
FMR LLC has filed a Schedule 13G, disclosing a beneficial ownership of 3,777,851.04 shares of Mirum Pharmaceuticals Inc. (MIRM) common stock, which represents 6.2% of the class. Abigail P. Johnson also holds sole dispositive power over the same number of shares. The filing indicates that while other persons may receive dividends or sale proceeds, no single person other than FMR LLC and Abigail P. Johnson holds more than five percent of the outstanding common stock.
2026-08-06 05:00:20
Mirum Pharmaceuticals reported strong Q2 2026 results, with net product sales of $176 million, and raised its full-year guidance to $680 million-$700 million. The company is preparing for the potential Q4 U.S. launch of zilurgisertib for FOP, following a favorable FDA meeting. However, the FDA recommended an additional Phase III study for volixibat in PSC, delaying its NDA filing to H1 2027, despite Mirum's disagreement and the drug's breakthrough therapy designation.
